Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Infect Immun ; 68(10): 6005-11, 2000 Oct.
Article in English | MEDLINE | ID: mdl-10992513

ABSTRACT

Mice infected with Schistosoma mansoni develop Th2 cytokine-mediated granulomatous pathology that is focused on the liver and intestines. In this study, transgenic mice constitutively expressing IL-9 were infected with S. mansoni and the outcome of infection was determined. Eight weeks after infection, transgenic mice with acute infections had a moderate increase in Th2 cytokine production but were overtly normal with respect to parasite infection and pathological responses. Transgenic mice with chronic infections died 10 weeks after infection, with 86% of transgenic mice dead by week 12 of infection, compared to 7% mortality in infected wild-type mice. Stimulation of mesenteric lymph node cells from infected transgenic mice with parasite antigen elicited elevated interleukin-4 (IL-4) and IL-5 production and reduced gamma interferon and tumor necrosis factor alpha production compared to the responses in wild-type mice. Morbid transgenic mice had substantial enlargement of the ileum, which was associated with muscular hypertrophy, mastocytosis, eosinophilia, goblet cell hyperplasia, and increased mucin expression. We also observed that uninfected transgenic mice exhibited alterations in their intestines. Although there was hepatic mastocytosis and eosinophilia in infected transgenic mice, there was no hepatocyte damage. Death of transgenic mice expressing IL-9 during schistosome infection was primarily associated with enteropathy. This study highlights the pleiotropic in vivo activity of IL-9 and demonstrates that an elevated Th2 cytokine phenotype leads to death during murine schistosome infection.


Subject(s)
Interleukin-9/metabolism , Intestinal Diseases, Parasitic/immunology , Intestinal Diseases, Parasitic/pathology , Schistosoma mansoni/immunology , Schistosomiasis mansoni/immunology , Th2 Cells/immunology , Animals , Chronic Disease , Cytokines/metabolism , Interleukin-9/genetics , Intestinal Diseases, Parasitic/mortality , Intestinal Diseases, Parasitic/parasitology , Intestine, Small/pathology , Liver/pathology , Mice , Mice, Transgenic , Schistosomiasis mansoni/mortality , Schistosomiasis mansoni/parasitology , Schistosomiasis mansoni/pathology
2.
J Chromatogr ; 428(2): 265-74, 1988 Jul 15.
Article in English | MEDLINE | ID: mdl-3215930

ABSTRACT

Buspirone and a buspirone metabolite, 1-(2-pyrimidinyl)piperazine (1-PP), are extracted from matrix using C18 extraction columns. The metabolite and its internal standard (d4-1-PP) are derivatized with pentafluorobenzoyl chloride to the corresponding amides. The 1-PP derivatives, buspirone and the buspirone internal standard (5-fluorobuspirone) are co-chromatographed. Chromatography and detection are performed using capillary gas chromatography with a fused-silica column and selected-ion monitoring-mass spectrometry. Linear range of the standard curves in plasma is 0.1-14 ng/ml for buspirone and 0.2-25 ng/ml for 1-PP with lower limits of quantitation of 0.1 and 0.2 ng/ml, respectively. In urine the linear range of the standard curves is 0.2-14 ng/ml for buspirone and 8-500 ng/ml for 1-PP with lower limits of quantitation of 0.2 and 8.0 ng/ml, respectively. Intra-assay accuracies were within 14% for buspirone and 1-PP in plasma and urine. Intra-assay precision was within 12% for both compounds in both matrices.


Subject(s)
Buspirone/analogs & derivatives , Buspirone/analysis , Buspirone/blood , Buspirone/urine , Drug Residues/analysis , Gas Chromatography-Mass Spectrometry , Humans , Indicators and Reagents , Tablets
3.
J Pharm Sci ; 77(3): 273-6, 1988 Mar.
Article in English | MEDLINE | ID: mdl-3286860

ABSTRACT

A specific and reproducible high-performance liquid chromatographic (HPLC) procedure was developed for the quantitative analysis of carboplatin (JM-8) in dog plasma ultrafiltrate. Plasma ultrafiltrate samples were generated using Amicon Centrifree micropartition systems or Amicon Centriflo cones, and injected onto a microBondapak NH2 column. The mobile phase consisted of acetonitrile:methanol:0.005 M sodium perchlorate, pH 2.4 (77-75:13-15:10, v/v/v); the flow rate was 1.5 mL/min. Detection was performed by monitoring UV absorbance of the column effluent at 229 nm. Carboplatin eluted between 9.5 and 11.0 min. The internal standard, JM-10, eluted between 11.0 and 13.0 min. The peak height ratio of carboplatin:internal standard versus carboplatin concentration was linear over a range of 0.2 to 20.0 micrograms/mL. The limit of quantitation was 0.2 microgram/mL. The intra-assay precision of this method, as measured by percent relative standard deviation (%RSD), was within 12% for the theoretical concentrations 0.5, 5.0, and 50.0 micrograms/mL. Accuracies were within 11%. The results of the validation procedures indicated that this procedure was accurate and specific.


Subject(s)
Antineoplastic Agents/blood , Organoplatinum Compounds/blood , Animals , Antineoplastic Agents/pharmacokinetics , Carboplatin , Chromatography, Liquid , Dogs , Organoplatinum Compounds/pharmacokinetics , Spectrophotometry, Ultraviolet , Ultrafiltration
4.
Cancer Chemother Pharmacol ; 21(3): 197-202, 1988.
Article in English | MEDLINE | ID: mdl-3282707

ABSTRACT

Carboplatin was administered i.v. to four groups of three male beagle dogs at doses of 3, 6, 12, and 24 mg/kg (60-580 mg/m2). Plasma samples were obtained at appropriate times and protein-free plasma ultrafiltrates (PU) were generated with Amicon Centrifree micropartition systems. Urine was collected at 24-h intervals for 96 h. PU and urine samples were analyzed for carboplatin by HPLC and for total platinum by atomic absorption spectrophotometry. Carboplatin accounted for about 90% of the free platinum in plasma. The Cmax and AUCinf values for carboplatin and for free platinum increased linearly with dose. The terminal elimination half-life and mean residence times for carboplatin and free platinum were each about 1 h. Total-body clearances for carboplatin (5.6 l/h per m2) and free platinum (5.1 l/h per m2) were constant over the dose range studied, as were the respective volumes of distribution (5.7 and 5.0 l/m2). A mean of 46% of the dose was excreted as carboplatin in 24-h urine; and by 72 h, 70% of the platinum administered was excreted in the urine. Free platinum was cleared by both renal and non-renal processes. These results show that a dose of carboplatin is rapidly excreted in the urine and that carboplatin and plasma-free platinum exhibit linear pharmacokinetics in the beagle dog.


Subject(s)
Dogs/metabolism , Organoplatinum Compounds/pharmacokinetics , Animals , Carboplatin , Chromatography, High Pressure Liquid , Half-Life , Male , Metabolic Clearance Rate , Organoplatinum Compounds/blood , Organoplatinum Compounds/urine , Tissue Distribution
5.
Pharmacotherapy ; 7(3): 72-9, 1987.
Article in English | MEDLINE | ID: mdl-2888096

ABSTRACT

Simultaneous administration of cimetidine and many benzodiazepine anxiolytics has resulted in decreased body clearance and marked prolongation of the half-life of these agents. The pharmacokinetic interaction of buspirone, a new nonbenzodiazepine anxiolytic, and cimetidine was studied in 10 healthy male volunteers. Each received, in order, buspirone 45 mg/day (days 1-7), no drug (days 8-14), cimetidine 1 g/day (days 15-21), buspirone 45 mg/day plus cimetidine 1 g/day (days 22-28), and cimetidine 1 g/day (days 29-31). Buspirone and 1-pyrimidinyl piperazine (1-PP), an active metabolite, pharmacokinetics, urinary excretion of cimetidine, a manual dexterity test, the Stroop color-word interference test, and a visual analog mood scale were evaluated on each treatment. There were no significant (p greater than 0.05) differences among treatments for any measurement except for a slight (31%) but significant (p less than 0.05) increase in the 1-PP Cmax value. These results suggest that within the normal therapeutic dosage ranges for both drugs, it is unlikely that a clinically significant interaction between them will occur.


Subject(s)
Anti-Anxiety Agents/metabolism , Cimetidine/pharmacology , Pyrimidines/metabolism , Adult , Anti-Anxiety Agents/adverse effects , Buspirone , Cimetidine/adverse effects , Cimetidine/urine , Drug Interactions , Half-Life , Humans , Kinetics , Male , Piperazines/metabolism , Psychomotor Performance/drug effects , Pyrimidines/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...